MX2023007716A - Procedimientos de tratamiento de enfermedades fibroticas. - Google Patents

Procedimientos de tratamiento de enfermedades fibroticas.

Info

Publication number
MX2023007716A
MX2023007716A MX2023007716A MX2023007716A MX2023007716A MX 2023007716 A MX2023007716 A MX 2023007716A MX 2023007716 A MX2023007716 A MX 2023007716A MX 2023007716 A MX2023007716 A MX 2023007716A MX 2023007716 A MX2023007716 A MX 2023007716A
Authority
MX
Mexico
Prior art keywords
compounds
fibrotic diseases
oxaphosphinane
analogues
cyclic
Prior art date
Application number
MX2023007716A
Other languages
English (en)
Inventor
Ludovic Clarion
Karine Chorro
Séverine Loiseau
Bernard Pau
Angel Argiles
Nathalie Gayrard
Original Assignee
Phostin Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phostin Therapeutics filed Critical Phostin Therapeutics
Publication of MX2023007716A publication Critical patent/MX2023007716A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
    • C07F9/657172—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and one oxygen atom being part of a (thio)phosphinic acid ester: (X = O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere al uso de compuestos fosfónicos heterocíclicos o composiciones que comprenden los mismos para el tratamiento de enfermedades fibróticas. En particular, la presente invención se refiere a compuestos de fórmula general (1) como se reivindica en la presente memoria descriptiva o composiciones que comprenden los mismos para su uso en el tratamiento de enfermedades fibróticas.
MX2023007716A 2021-01-13 2022-01-13 Procedimientos de tratamiento de enfermedades fibroticas. MX2023007716A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21305031 2021-01-13
PCT/EP2022/050652 WO2022152795A1 (en) 2021-01-13 2022-01-13 Cyclic oxaphosphinane compounds and analogues thereof for treating fibrotic diseases

Publications (1)

Publication Number Publication Date
MX2023007716A true MX2023007716A (es) 2023-09-22

Family

ID=74215855

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007716A MX2023007716A (es) 2021-01-13 2022-01-13 Procedimientos de tratamiento de enfermedades fibroticas.

Country Status (11)

Country Link
US (1) US20240082271A1 (es)
EP (1) EP4277633A1 (es)
JP (1) JP2024504643A (es)
KR (1) KR20230131892A (es)
CN (1) CN116685310A (es)
AU (1) AU2022209089A1 (es)
CA (1) CA3203692A1 (es)
MX (1) MX2023007716A (es)
PH (1) PH12023551898A1 (es)
TW (1) TW202237093A (es)
WO (1) WO2022152795A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025132992A1 (en) 2023-12-20 2025-06-26 Phost'in Therapeutics DEUTERATED DERIVATIVES OF 3-HYDROXY-4,5-BIS-BENZYLOXY-6-BENZYLOXYMETHYL-2-PHENYL-2-OXO-2λ5-[1,2]OXAPHOSPHINANE

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2170912B3 (en) * 2007-07-05 2022-06-15 Centre National De La Recherche Scientifique New phosphorus containing heterocyclic compounds, sugar analogues, and compositions having anti-cancer activity containing the same
JP6152389B2 (ja) * 2012-01-26 2017-06-21 アンジオン バイオメディカ コーポレーション 抗線維化化合物及びその使用
FR3002451B1 (fr) * 2013-02-25 2015-06-26 Centre Nat Rech Scient Heterocycles phosphores analogues de sucres a activite antimetastatique
EP3295944A1 (en) 2016-09-20 2018-03-21 Phost'in Crystalline polymorphic form of 3-hydroxy-4,5-bis-benzyloxy-6-benzyloxymethyl-2-phenyl-2-oxo-2lambda5-[1,2]oxaphosphinane

Also Published As

Publication number Publication date
PH12023551898A1 (en) 2023-12-04
AU2022209089A9 (en) 2024-02-08
TW202237093A (zh) 2022-10-01
WO2022152795A1 (en) 2022-07-21
CN116685310A (zh) 2023-09-01
CA3203692A1 (en) 2022-07-21
JP2024504643A (ja) 2024-02-01
US20240082271A1 (en) 2024-03-14
KR20230131892A (ko) 2023-09-14
EP4277633A1 (en) 2023-11-22
AU2022209089A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
PY2165555A (es) Compuestos antivirales que contienen nitrilos
BR112021022758A2 (pt) Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos
CO2021005226A2 (es) Nuevos compuestos antihelmínticos
JOP20220131A1 (ar) مركبات أمينو كينولون تحمل بدائل تستخدم كمثبطات لـ dgkalpha من أجل تنشيط المناعة
MX2020006438A (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1.
MX2022006700A (es) Compuestos poliheterociclicos como inhibidores de mettl3.
DOP2019000110A (es) 1,2,4–triazolonas 2,4,5–trisustituidas
CR20230485A (es) Derivados de fósforo como nuevos inhibidores de sos1
CO2023014721A2 (es) Compuestos heterocíclicos
CO2022000481A2 (es) Inhibidores de enzimas
PE20151892A1 (es) Compuestos tetraciclicos sustituidos con heterociclo y metodos de uso de los mismos para el tratamiento de enfermedades viricas
CL2020002099A1 (es) Compuestos herbicidas de 3-azaspiro (5.5) undecano - 8.10 - diona.
MX2021002215A (es) Derivados de tetrahidropiridopirimidina como moduladores de ahr.
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
BR112018014540A2 (pt) formulações/composições compreendendo inibidor de btk
BR112022001054A2 (pt) Inibidores enzimáticos
ECSP21088111A (es) Analogos de 3–(5–metil–1,3–tiazol–2–il)–n–{(1r)–1–[2–(trifluor–metil)pirimidin–5–il]etil}benzamida
CL2023003921A1 (es) Inhibidores de transglutaminasas
CO2025018165A2 (es) Agonistas de trem2
CL2023003979A1 (es) Inhibidores de las transglutaminasas
MX2023007716A (es) Procedimientos de tratamiento de enfermedades fibroticas.
CO2023008475A2 (es) Inhibidores de enzimas
CL2022000320A1 (es) Compuestos adecuados para el tratamiento y la profilaxis del desgaste muscular y otras afecciones
UY39172A (es) Análogos de nucleósido bi- y monocíclicos para el tratamiento de la hepatitis e
CO2024000832A2 (es) Inhibidores de transglutaminasas